Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Zhaoke Ophthalmology's share price for the quarter that ended in Dec. 2025 was HK$2.96. Zhaoke Ophthalmology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 547.97 Mil. Therefore, Zhaoke Ophthalmology's market cap for the quarter that ended in Dec. 2025 was HK$1,621.99 Mil.
Zhaoke Ophthalmology's quarterly market cap
increased
from Dec. 2024 (HK$660.83 Mil) to Jun. 2025 (HK$1,419.96 Mil) and
increased
from Jun. 2025 (HK$1,419.96 Mil) to Dec. 2025 (HK$1,621.99 Mil).
Zhaoke Ophthalmology's annual market cap
declined
from Dec. 2023 (HK$2,157.25 Mil) to Dec. 2024 (HK$660.83 Mil) but then
increased
from Dec. 2024 (HK$660.83 Mil) to Dec. 2025 (HK$1,621.99 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zhaoke Ophthalmology's Enterprise Value for Today is HK$582.31 Mil.
Zhaoke Ophthalmology (HKSE:06622) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zhaoke Ophthalmology Market Cap Related Terms
Zhaoke Ophthalmology Market Cap Historical Data
* Premium members only.
The historical data trend for Zhaoke Ophthalmology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06622 vs VRTX, REGN, MRNA: Market Cap Comparison
For the Biotechnology subindustry, Zhaoke Ophthalmology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Market Cap distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Zhaoke Ophthalmology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology (HKSE:06622) has a Market Cap of HK$1,383.99 Mil as of Sep. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhaoke Ophthalmology and its competitors. According to the industry distribution chart, Zhaoke Ophthalmology ranks #637 out of 1421 companies in the Biotechnology industry, placing it in the top 44.8%.
Is Zhaoke Ophthalmology's Market Cap too high?
Zhaoke Ophthalmology's current Market Cap is HK$1,383.99 Mil. Based on the distribution chart, Zhaoke Ophthalmology ranks #637 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhaoke Ophthalmology ranks #637 out of 1421 companies for Market Cap. This puts Zhaoke Ophthalmology in the upper half of its industry. The industry median Market Cap is 120.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.76, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhaoke Ophthalmology and its competitors. For the Biotechnology industry, the median Market Cap is 120.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhaoke Ophthalmology's current Market Cap is HK$1,383.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Based on GuruFocus' analysis, Zhaoke Ophthalmology (HKSE:06622) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.60, compared to a current price of HK$2.53 — trading 2.7% below its estimated fair value. The current Market Cap is HK$1,383.99 Mil. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Zhaoke Ophthalmology (HKSE:06622), the current Market Cap is HK$1,383.99 Mil as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhaoke Ophthalmology (HKSE:06622) Overvalued in 2026?
Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued.
The current stock price of HK$2.53 is trading 2.7% below its estimated GF Value™ of HK$2.60.
GuruFocus considers Zhaoke Ophthalmology to be Fairly Valued.
Key valuation signals for HKSE:06622:
Market Cap: HK$1,383.99 Mil
GF Value™: HK$2.60 vs. price of HK$2.53 (2.7% below fair value)
No single metric tells the full story. See the HKSE:06622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score
Get the complete analysis for HKSE:06622
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06622 has been successfully added to your 
